ERBB2 and breast cancer: Here, we registered the EARLY-MYO-BC study in order to describe pyrotinib’s cardiac impacts and to further determine whether novel dual HER2 blockade using pyrotinib plus trastuzumab is non-inferior to the NCCN-recommended regimen (pertuzumab plus trastuzumab) with regard to cardiac safety during the course of neoadjuvant treatment.